Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Beyond HER2: Targeting the ErbB receptor family in breast cancer
Joshua Z. Drago, Emanuela Ferraro, Nour Abuhadra, et al.
Cancer Treatment Reviews (2022) Vol. 109, pp. 102436-102436
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Bispecific antibody drug conjugates: Making 1+1>2
Yilin Gu, Zhijia Wang, Yuxi Wang
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 5, pp. 1965-1986
Open Access | Times Cited: 36
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance
Jing Wang, Baizhou Li, Meng Luo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 28
Unveiling promising breast cancer biomarkers: an integrative approach combining bioinformatics analysis and experimental verification
Ali Golestan, Ahmad Tahmasebi, Nafiseh Maghsoodi, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 12
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
Gabriele Antonarelli, Chiara Corti, Paolo Tarantino, et al.
ESMO Open (2023) Vol. 8, Iss. 4, pp. 101608-101608
Open Access | Times Cited: 17
Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer
Yu Cao, Sergey Efetov, Mingze He, et al.
Archivum Immunologiae et Therapiae Experimentalis (2023) Vol. 71, Iss. 1
Closed Access | Times Cited: 14
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response
Fara Brasó‐Maristany, Juan M. Ferrero-Cafiero, Claudette Falato, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Covalent inhibition of epidermal growth factor receptor using a long-lived iridium(III)-afatinib probe
Sang-Cuo Nao, Lingtan Kong, Daniel Shiu‐Hin Chan, et al.
International Journal of Biological Macromolecules (2024) Vol. 259, pp. 129211-129211
Closed Access | Times Cited: 4
ERBB3-related gene PBX1 is associated with prognosis in patients with HER2-positive breast cancer
Shaobo Mo, Zhong Hai-ming, Wei-Ping Dai, et al.
BMC Genomic Data (2025) Vol. 26, Iss. 1
Open Access
HER2-positive gastric cancer: from targeted therapy to CAR-T cell therapy
Qiang Shao, Junge Deng, Haoran Wu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
PCSK9 Promotes the Malignancy of Triple‐negative Breast Cancer Cells by Reducing Cholesterol Levels at the Plasma Membrane to Activate EGFR and HER3
Tianhong Li, Renfei Wu, Kathy Qian Luo
Advanced Science (2025)
Open Access
PAK5 promotes the trastuzumab resistance by increasing HER2 nuclear accumulation in HER2-positive breast cancer
Xin Zhao, Yang Li, Hongyan Zhang, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access
Targeted Therapy and Immunotherapy for Heterogeneous Breast Cancer
Xiaolu Sun, Kuai Liu, Shuli Lu, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5456-5456
Open Access | Times Cited: 16
HER2GAN: Overcome the Scarcity of HER2 Breast Cancer Dataset Based on Transfer Learning and GAN Model
Mohammad Mobin Mirimoghaddam, Jafar Majidpour, Fakhereh Pashaei, et al.
Clinical Breast Cancer (2023) Vol. 24, Iss. 1, pp. 53-64
Closed Access | Times Cited: 8
SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs
Wenjing Li, Chengying Xie, Xi Zhu, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 4, pp. 857-866
Closed Access | Times Cited: 3
HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs
Huilan Zeng, Wei Wang, Lin Zhang, et al.
Cancer Drug Resistance (2024)
Open Access | Times Cited: 3
GPR37 promotes colorectal cancer against ferroptosis by reprogramming lipid metabolism via p38-SCD1 axis
Jiamin Zhou, Xigan He, Weixing Dai, et al.
APOPTOSIS (2024)
Closed Access | Times Cited: 2
Dysregulated Signaling Pathways in Canine Mammary Tumor and Human Triple Negative Breast Cancer: Advances and Potential Therapeutic Targets
Chen Mei, Ying Liu, Zhenyi Liu, et al.
International Journal of Molecular Sciences (2024) Vol. 26, Iss. 1, pp. 145-145
Open Access | Times Cited: 2
A Preliminary Evaluation of the Prognostic Role of HER-2 and HER-3 Immunohistochemical Expression in Canine Melanomas
Francesca Parisi, Luigi Aurisicchio, Arianna Pecorari, et al.
Animals (2024) Vol. 14, Iss. 10, pp. 1400-1400
Open Access | Times Cited: 1
SON is an essential RNA splicing factor promoting ErbB2 and ErbB3 expression in breast cancer
Joshua B. Phillips, Seong‐Sik Park, Cheng-Han Lin, et al.
British Journal of Cancer (2024)
Closed Access | Times Cited: 1
Advances in HER2-Targeted Treatment for Advanced/Metastatic Urothelial Carcinoma
Mengnan Qu, Li Zhou, Xieqiao Yan, et al.
Bladder (1970) Vol. 10, Iss. 1, pp. 1-1
Open Access | Times Cited: 10
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
Sarina A. Piha‐Paul, Chieh Tseng, Hai T. Tran, et al.
Cancer Chemotherapy and Pharmacology (2023) Vol. 92, Iss. 2, pp. 107-118
Open Access | Times Cited: 3
Synthesis of novel pyrimido[4,5‐b]quinoline derivatives as dual EGFR/HER2 inhibitors as anticancer agents
Nahla Said M. Ibrahim, Hanan H. Kadry, Ashraf F. Zaher, et al.
Archiv der Pharmazie (2023) Vol. 357, Iss. 3
Closed Access | Times Cited: 3
Biomarkers and translational research approaches in breast cancer—an update
Angelika M. Starzer, Anna S. Berghoff, Rupert Bartsch
memo - Magazine of European Medical Oncology (2022) Vol. 16, Iss. 1, pp. 42-46
Open Access | Times Cited: 4
Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization
Aswin Shanmugalingam, Kerry Hitos, Nirmala Pathmanathan, et al.
Breast Cancer Research and Treatment (2023) Vol. 198, Iss. 1, pp. 143-148
Closed Access | Times Cited: 1
ERBB2 Targeting Reveals a Significant Suppression of Tumorigenesis in Murine Endometrial Cancer with Pten Mutation
Krystina Dunston, Mark Hunter, Eric Johannesen, et al.
Reproductive Sciences (2024) Vol. 31, Iss. 8, pp. 2458-2467
Closed Access
Page 1 - Next Page

Scroll to top